早期NKTCL中IMRT的风险适应性生存获益:中国淋巴瘤协作组多中心研究
该回顾性多中心研究纳入16家中国机构1691例接受高剂量放疗(≥45 Gy)的早期结外鼻型NK/T细胞淋巴瘤患者,比较IMRT与3D-CRT的生存获益。IMRT组981例(58%),3D-CRT组710例(42%)。未校正5年OS和PFS分别为IMRT组75.9%和67.6%,3D-CRT组68.9%(P = .004)和58.2%(P < .001)。倾向性评分匹配和多因素分析后,IMRT仍与OS和PFS改善显著相关;风险适应性生存获益特征可用于选择患者和治疗决策。
要点
- IMRT组5年OS 75.9%、PFS 67.6%,均优于3D-CRT组的68.9%和58.2%。
- 倾向性评分匹配和多因素分析后,IMRT仍与OS和PFS改善显著相关。
- IMRT对高危和中高危患者显著改善OS和PFS,对低危和中低危患者获益有限。
核心结论
- 与3D-CRT相比,IMRT显著改善高危和中高危早期NKTCL患者的OS和PFS,但对低危或中低危患者获益有限。
- IMRT的风险适应性生存获益特征可用于选择患者和制定治疗决策。
研究设计与样本
- 回顾性研究,纳入16家中国机构接受高剂量放疗(≥45 Gy)的早期结外鼻型NK/T细胞淋巴瘤患者1691例。
- 按危险因素数目分为低危(无因素)、中低危(1个因素)、中高危(2个因素)和高危(3-5个因素)4组。
- 981例(58%)接受IMRT,710例(42%)接受3D-CRT。
主要发现
- 未校正5年OS:IMRT组75.9% vs 3D-CRT组68.9%(P = .004)。
- 未校正5年PFS:IMRT组67.6% vs 3D-CRT组58.2%(P < .001)。
- 倾向性评分匹配和多因素分析校正混杂因素后,IMRT仍与OS和PFS改善显著相关。
- 接受现代化疗方案的患者中,IMRT的OS和PFS获益持续存在。
- 与3D-CRT相比,IMRT显著改善高危和中高危患者的OS和PFS,对低危或中低危患者获益有限。
临床怎么用
- 作者认为,IMRT的风险适应性生存获益特征可用于选择患者和制定治疗决策。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This study evaluated the survival benefit of intensity-modulated radiation therapy (IMRT) compared with 3-dimension conformal radiation therapy (3D-CRT) in a large national cohort of patients with early-stage extranodal nasal-type natural killer/T-cell lymphoma (NKTCL). This retrospective study reviewed patients with early-stage NKTCL treated with high-dose radiation therapy (RT; ≥45 Gy) at 16 Chinese institutions. Patients were stratified into 1 of 4 risk groups based on the number of risk factors: low risk (no factors), intermediate-low risk (1 factor), intermediate-high risk (2 factors), and high-risk (3-5 factors). Of the 1691 patients, 981 (58%) received IMRT, and 710 (42%) received 3D-CRT. Unadjusted 5-year overall survival (OS) and progression-free survival (PFS) were 75.9% and 67.6%, respectively, for IMRT compared with 68.9% (P = .004) and 58.2% (P < .001), respectively, for 3D-CRT. After propensity score match and multivariable analyses to account for confounding factors, IMRT remained significantly associated with improved OS and PFS. The OS and PFS benefits of IMRT persisted in patients treated with modern chemotherapy regimens. Compared with 3D-CRT, IMRT significantly improved OS and PFS for high-risk and intermediate-high-risk patients but provided limited benefits for low-risk or intermediate-low-risk patients. A risk-adapted survival benefit profile of IMRT can be used to select patients and make treatment decisions.
引用
- Wu T, Yang Y, Zhu SY, et al. Risk-adapted survival benefit of IMRT in early-stage NKTCL: a multicenter study from the China Lymphoma Collaborative Group. Blood Adv. 2018. PMID: 30242098. doi:10.1182/bloodadvances.2018021311
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。